Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration

Inclusion Criteria: * Male or female, 18-65 years of age * If female: non-lactating; non-pregnant; and incapable of becoming pregnant, or taking specific precautions to avoid becoming pregnant before and during study * Normal clinical laboratory parameters * Adequate venous access in both upper extremities * Agreeing to refrain from smoking and from ingesting any alcohol or caffeine-containing products before and during the study * Good health based on medical history, physical examination and laboratory tests * Non-smoking; or smoking less than 10 cigarettes per day and willing to refrain from use of nicotine products before and during study Exclusion Criteria: * Received a cephalosporin within the 21 days prior to study or anticipated to receive non-study cephalosporin during study * Pregnant or breast-feeding. * Previously exposed to a hyaluronidase drug product * Medical condition presenting unacceptable safety risk or likely to prevent completion of study * Known hypersensitivity to hyaluronidase or any other ingredient in HYLENEX recombinant * Contraindication to ceftriaxone, including known allergy to beta-lactam antibiotics * Local condition precluding subcutaneous injection or injection site evaluation * History of gastrointestinal disease (in particular colitis) * Consumption of caffeine- or other methylxanthine-containing beverage within 24 hours before and/or during the PK sampling period * Participation in study of any investigational drug or device within 30 days before this study * Serum hemoglobin \<12 g/dL. * Blood donation or significant loss of blood within 56 days, or plasma donation within 7 days, prior to study * Medical history/condition, screening physical examination finding or clinical laboratory result precluding safe participation in study, or which might adversely effect interpretation of study results * History of drug or alcohol abuse within 2 years prior to study